142 related articles for article (PubMed ID: 26171805)
1. Sexual dysfunction: PDE5i and melanoma-correlation is not causation.
Stone L
Nat Rev Urol; 2015 Aug; 12(8):418. PubMed ID: 26171805
[No Abstract] [Full Text] [Related]
2. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Seftel AD
J Urol; 2016 Mar; 195(3):713. PubMed ID: 26887740
[No Abstract] [Full Text] [Related]
3. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Penson DF
J Urol; 2015 Dec; 194(6):1710-1. PubMed ID: 26582698
[No Abstract] [Full Text] [Related]
4. Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Tasian GE; Cooperberg MR
Eur Urol; 2016 Feb; 69(2):374-5. PubMed ID: 26758522
[No Abstract] [Full Text] [Related]
5. Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Damber JE
Eur Urol; 2015 Dec; 68(6):1102. PubMed ID: 26545574
[No Abstract] [Full Text] [Related]
6. Sildenafil may elevate melanoma risk.
Grichnik JM
Dermatol Ther; 2014; 27(5):313. PubMed ID: 25285874
[No Abstract] [Full Text] [Related]
7. Role of sildenafil in melanoma incidence and mortality.
Robinson JK
JAMA Intern Med; 2014 Jun; 174(6):970-1. PubMed ID: 24710720
[No Abstract] [Full Text] [Related]
8. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans.
Christie A; Vera PL; Higgins M; Kumar S; Lane M; Preston D
Urology; 2019 Apr; 126():116-120. PubMed ID: 30735744
[TBL] [Abstract][Full Text] [Related]
9. [Erectile dysfunction, PDE5A inhibitors and melanoma].
Schmutz JL
Ann Dermatol Venereol; 2015 Dec; 142(12):800-1. PubMed ID: 26293983
[No Abstract] [Full Text] [Related]
10. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
11. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar E; Li S; Tang J; Eisenberg ML
J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
[TBL] [Abstract][Full Text] [Related]
12. [Phosphodiesterase-5 inhibitors for erectile dysfunction: Adverse reactions and countermeasures].
Jiang R; Wu BC
Zhonghua Nan Ke Xue; 2016 Feb; 22(2):99-103. PubMed ID: 26939391
[TBL] [Abstract][Full Text] [Related]
13. [Sildenafil and increase in melanoma risk].
Saillen E
Rev Med Suisse; 2014 Jun; 10(433):1268-9. PubMed ID: 25004777
[No Abstract] [Full Text] [Related]
14. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Deng T; Duan X; Liu B; Lan Y; Cai C; Zhang T; Zhu W; Mai Z; Wu W; Zeng G
Neoplasma; 2018; 65(2):216-221. PubMed ID: 29534582
[TBL] [Abstract][Full Text] [Related]
15. Newer phosphodiesterase inhibitors: comparison with established agents.
McNamara ER; Donatucci CF
Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
[TBL] [Abstract][Full Text] [Related]
16. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.
Corona G; Rastrelli G; Burri A; Serra E; Gianfrilli D; Mannucci E; Jannini EA; Maggi M
Andrology; 2016 Nov; 4(6):1002-1009. PubMed ID: 27636710
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Lian Y; Yin H; Pollak MN; Carrier S; Platt RW; Suissa S; Azoulay L
Eur Urol; 2016 Nov; 70(5):808-815. PubMed ID: 27178449
[TBL] [Abstract][Full Text] [Related]
18. Erectile disfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects.
Cocci A; Romano A; Morelli G; Frediani D; Sodi A; Russo GI
Arch Ital Urol Androl; 2020 Dec; 92(4):. PubMed ID: 33348949
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
Lee M; Sharifi R
Drugs Aging; 2018 Mar; 35(3):175-187. PubMed ID: 29464656
[TBL] [Abstract][Full Text] [Related]
20. The Relationship Between Phosphodiesterase-5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.
Pomeranz HD
J Neuroophthalmol; 2016 Jun; 36(2):193-6. PubMed ID: 26720519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
